SBI Securities Co. Ltd. Makes New Investment in VanEck Pharmaceutical ETF (NASDAQ:PPH)

SBI Securities Co. Ltd. bought a new position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 332 shares of the company’s stock, valued at approximately $29,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PPH. Assetmark Inc. grew its stake in shares of VanEck Pharmaceutical ETF by 5.8% during the third quarter. Assetmark Inc. now owns 6,491 shares of the company’s stock worth $617,000 after buying an additional 354 shares during the last quarter. Apollon Wealth Management LLC grew its stake in shares of VanEck Pharmaceutical ETF by 3.4% in the third quarter. Apollon Wealth Management LLC now owns 28,632 shares of the company’s stock worth $2,721,000 after purchasing an additional 946 shares during the last quarter. Harbour Investments Inc. grew its stake in shares of VanEck Pharmaceutical ETF by 16.6% in the third quarter. Harbour Investments Inc. now owns 3,425 shares of the company’s stock worth $325,000 after purchasing an additional 488 shares during the last quarter. Oppenheimer & Co. Inc. grew its stake in shares of VanEck Pharmaceutical ETF by 7.9% in the third quarter. Oppenheimer & Co. Inc. now owns 13,445 shares of the company’s stock worth $1,278,000 after purchasing an additional 990 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its stake in shares of VanEck Pharmaceutical ETF by 33.6% in the third quarter. Thrivent Financial for Lutherans now owns 234,890 shares of the company’s stock worth $22,322,000 after purchasing an additional 59,025 shares during the last quarter.

VanEck Pharmaceutical ETF Stock Down 1.1 %

Shares of VanEck Pharmaceutical ETF stock opened at $91.50 on Thursday. VanEck Pharmaceutical ETF has a twelve month low of $84.48 and a twelve month high of $99.51. The stock has a market cap of $570.96 million, a price-to-earnings ratio of 30.55 and a beta of 0.72. The company’s fifty day moving average is $89.27 and its 200 day moving average is $91.26.

VanEck Pharmaceutical ETF Increases Dividend

The firm also recently disclosed a dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 27th were paid a $0.411 dividend. This is a boost from VanEck Pharmaceutical ETF’s previous dividend of $0.36. The ex-dividend date was Friday, December 27th.

About VanEck Pharmaceutical ETF

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.